semaglutide peptide canada | The Labs Canada first in G7 to

ERIS Lifesciences & NATCO Pharma offer even cheaper options, as low as 1,290 a month

launch expected in early 2026 This approval expands treatment options and marks a major milestone for GLP-1 therapies

If you came to struggle with gastroparesis, bowel obstruction or vision loss as a result of using semaglutide, you might be eligible to file a claim

Discover expert tips on how to store peptides safely

Explore the combined effects of semaglutide and the keto diet

Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution